Circular Bumps On Palms

Orlistat (Xenical)

Orlistat is a drug that was approved in early 1999 by the FDA (Food and Drug Administration) for use in weight reduction treatments up to 2 years.

As in the case of Sibutramine, Orlistat does not replace the diet, that is, any weight reduction treatment must be installed on the basis of dietoterápico treatment, increased activity physical and positive change in lifestyle. Not obtained the expected results, may be assessed the possibility of using these drugs without neglecting the above points.

Recommended Dose

pharmacodynamic studies have determined that the doses of 120 mg of orlistat 3 times daily (with each main meal ) is optimal, but it should be noted that these values \u200b\u200bmust be adapted to the eating habits of each country. In most South American countries, the consumption of fats in foods is limited to lunch and dinner, unlike countries like the U.S. where breakfast has a significant amount of lipids.

Since orlistat works by reducing the absorption of fat consumed at each meal, does not justify the administration of drugs in foods that do not possess significant amounts of fat. Therefore it is recommended orlistat administration only during the course of lunch and dinner.

Also, you can skip taking orlistat when you eat a meal devoid of fat (eg, a lunch consisting of rice with grated carrot, no added oil) and resume treatment with the next meal (dinner).


Adverse effects

The main adverse effects occur at the gastrointestinal level. Usually occur early in treatment and tend to decrease with continued administration of the drug. The adverse effects most frequently reported were associated with a decreased fat absorption, and included diarrhea oily, steatorrhea and incontinence.

systemic adverse effects attributable to orlistat were negligible. Patients should maintain a low fat intake to prevent or reduce these effects.

Because orlistat may decrease the absorption of fat soluble vitamins, recommended daily administration of common multivitamin supplements during the treatment period to prevent abnormalities in the serum concentration of vitamins. Fat-soluble vitamins should be administered at least two hours before or two hours after taking orlistat, it is recommended to do so before bedtime.

Conclusion

Based on the analyzed studies, orlistat is an effective drug for the treatment of obesity in patients who adhere to a hypocaloric diet and normograsa (30% VCT). Not addictive or produce a rebound effect. It should not be considered a "magic pill" that comes to supplant all known treatments. If it is not accompanied by proper diet tailored and supervised by a specialist, does not report any benefit.